Today: 21 May 2026
Nanya Technology stock price in focus as 2408 heads into Taiwan open on DRAM squeeze
26 January 2026
2 mins read

Nanya Technology stock price in focus as 2408 heads into Taiwan open on DRAM squeeze

Taipei, Jan 26, 2026, 07:02 GMT+8 — Premarket

  • Shares of Nanya Technology ended Friday at T$271.50, marking a 1.9% rise.
  • The DRAM maker signaled a strong profit rebound in Q4 and revealed plans for increased spending in 2026.
  • Investors are eyeing demand signals from device makers and await Nanya’s next monthly revenue update, set for Feb. 10.

Shares of Taiwan DRAM maker Nanya Technology Corp (2408.TW) caught attention ahead of Monday’s open after closing Friday at T$271.50, up 1.9%. The company reported a fourth-quarter net income of T$11.083 billion last week and outlined a 2026 capital expenditure plan around T$50 billion, pending board approval. This move supports a new fab with equipment move-in slated for early 2027.

The stock is benefiting from a renewed search for “picks-and-shovels” plays in the AI boom, as memory names regain momentum following a pause in Big Tech’s earlier rally. Memory and data-storage shares have surged amid forecasts of prolonged tight supply, with some predicting shortages stretching through 2028. Financial Times

DRAM, short for dynamic random access memory, serves as the working memory in computers and servers. For Nanya, the immediate challenge is seeing if stronger prices for standard DRAM chips can boost margins without sparking the typical drop in demand from PCs and smartphones.

Nanya president Lee Pei-ing expects chip prices to rise further this quarter amid tight supply. “Artificial intelligence [AI] servers and general-purpose servers are driving DRAM demand in 2026,” Lee noted, highlighting shortages across DDR4 and DDR5 products. The company is also set to boost capital spending to a record T$50 billion this year to speed up construction of a new plant, aiming for volume production by the first half of 2027. Taipei Times

Supply increases are on the way in the sector, but they’re slow to arrive. Micron Technology has inked a letter of intent to acquire Powerchip Semiconductor Manufacturing’s P5 fab for $1.8 billion. Micron anticipates that this deal will boost DRAM wafer production beginning in the second half of 2027.

Rising memory costs are starting to ripple through the supply chain. Reuters cites IDC and Counterpoint, which now predict global smartphone sales will drop by at least 2% in 2026, while the PC market could shrink around 4.9%. Manufacturers are hiking prices to cover soaring memory expenses. “It is certainly going to show up as higher prices for consumers,” said eMarketer analyst Jacob Bourne. Investors will be eyeing Apple’s Jan. 29 earnings and Dell’s on Feb. 26 for signs of how much demand is feeling the pinch. Reuters

Taiwan’s Compal, a major player in notebook and PC manufacturing, has signaled that the effects will persist. “It’s a true super cycle (in memory chips) that we haven’t really seen,” CEO Anthony Peter Bonadero said, noting memory chips could take up a much larger portion of a PC’s materials cost than usual. Reuters

Traders are keen to see if the momentum in global memory stocks spills over into Taiwan’s cash market on Monday. They’re also tracking if DRAM pricing talk holds steady, with suppliers focusing on high-bandwidth memory for AI accelerators. On the flip side, a slight dip in end-demand could quickly upend the pricing narrative.

Nanya’s next key event is its January operating revenue report, due by Feb. 10 as mandated for Taiwan-listed firms. Investors want to see if higher prices are actually boosting sales, not just making headlines.

Stock Market Today

  • Adherium Plans 100-to-1 Share Consolidation to Boost Market Visibility
    May 20, 2026, 9:55 PM EDT. Adherium (ASX:ADR) announced a 100-to-1 share consolidation to be voted on 19 June 2026, aiming to improve its stock's marketability and trading profile. Despite FDA clearance and shipment of over 180,000 Hailie Smartinhaler devices, the company's low share price and large share count have hindered investor interest. The consolidation will convert every 100 shares into one, lifting the stock price to meet institutional purchase requirements and broker platform filters typically excluding sub-cent securities. While the move doesn't affect the company's market capitalization or underlying business, it seeks to attract more serious investors by changing the stock's optics. The Hailie platform remains Adherium's key asset, offering remote monitoring of respiratory treatments. The consolidation is viewed as a structural reset rather than direct value creation.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Zhongji Innolight (300308.SZ) stock: China’s new fund-favorite faces a Monday test after a 5.8% slide
Previous Story

Zhongji Innolight (300308.SZ) stock: China’s new fund-favorite faces a Monday test after a 5.8% slide

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz
Next Story

Stock Market Today 26.01.2026

Go toTop